tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

IART Stock Latest News

Integra LifeSciences sees Q1 adjusted EPS 72c-76c, consensus 79c
The FlyIntegra LifeSciences sees Q1 adjusted EPS 72c-76c, consensus 79c
29d ago
IART
Integra LifeSciences sees FY23 adjusted EPS $3.43-$3.51, consensus $3.52
The FlyIntegra LifeSciences sees FY23 adjusted EPS $3.43-$3.51, consensus $3.52
29d ago
IART
Integra LifeSciences reports Q4 adjusted EPS 94c, consensus 90c
The FlyIntegra LifeSciences reports Q4 adjusted EPS 94c, consensus 90c
29d ago
IART
Integra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
Press ReleasesIntegra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
29d ago
IART
Integra LifeSciences to Host Fourth Quarter 2022 Financial Results Conference Call on February 22, 2023
Press ReleasesIntegra LifeSciences to Host Fourth Quarter 2022 Financial Results Conference Call on February 22, 2023
1M ago
IART
Piper Sandler maintains cautious stance on Integra LifeSciences
The FlyPiper Sandler maintains cautious stance on Integra LifeSciences
2M ago
IART
Integra LifeSciences sees Q4 EPS 92c-96c, consensus 89c
The FlyIntegra LifeSciences sees Q4 EPS 92c-96c, consensus 89c
2M ago
IART
Integra LifeSciences confirms Carrie Anderson to step down as CFO
The FlyIntegra LifeSciences confirms Carrie Anderson to step down as CFO
2M ago
IART
Campbell Soup names Carrie Anderson as new CFO
The FlyCampbell Soup names Carrie Anderson as new CFO
2M ago
CPB
IART
Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
Press ReleasesIntegra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
2M ago
IART
Integra LifeSciences reiterates plans to initiate $150M share buyback in 2023
The FlyIntegra LifeSciences reiterates plans to initiate $150M share buyback in 2023
2M ago
IART
Integra sees FY22 adjusted EPS above $3.29-$3.33 range, consensus $3.30
The FlyIntegra sees FY22 adjusted EPS above $3.29-$3.33 range, consensus $3.30
2M ago
IART
Integra LifeSciences sees Q4 revenue $397M-$398M, consensus $397.5M
The FlyIntegra LifeSciences sees Q4 revenue $397M-$398M, consensus $397.5M
2M ago
IART
Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference
Press ReleasesIntegra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference
3M ago
IART
Integra LifeSciences price target raised to $60 from $50 at Citi
The FlyIntegra LifeSciences price target raised to $60 from $50 at Citi
3M ago
IART
Integra LifeSciences Completes the Acquisition of Surgical Innovation Associates
Press ReleasesIntegra LifeSciences Completes the Acquisition of Surgical Innovation Associates
4M ago
IART
Integra LifeSciences plans $150M share repurchase
The FlyIntegra LifeSciences plans $150M share repurchase
4M ago
IART
Integra LifeSciences to acquire Surgical Innovation Associates for $50M upfront
The FlyIntegra LifeSciences to acquire Surgical Innovation Associates for $50M upfront
4M ago
IART
Integra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase
Press ReleasesIntegra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase
4M ago
IART
Integra LifeSciences Reports Third Quarter 2022 Financial Results
Press ReleasesIntegra LifeSciences Reports Third Quarter 2022 Financial Results
5M ago
IART
Integra LifeSciences to Host Third Quarter 2022 Financial Results Conference Call on October 26, 2022
Press ReleasesIntegra LifeSciences to Host Third Quarter 2022 Financial Results Conference Call on October 26, 2022
6M ago
IART
Integra LifeSciences Announces Key Executive Appointment
Press ReleasesIntegra LifeSciences Announces Key Executive Appointment
6M ago
IART
Integra LifeSciences Publishes Its Inaugural ESG Report
Press ReleasesIntegra LifeSciences Publishes Its Inaugural ESG Report
6M ago
IART
Integra LifeSciences Announces Participation in Upcoming Investor Conferences
Press ReleasesIntegra LifeSciences Announces Participation in Upcoming Investor Conferences
7M ago
IART
Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO
Press ReleasesIntegra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO
7M ago
IART
Integra LifeSciences Reports Second Quarter 2022 Financial Results
Press ReleasesIntegra LifeSciences Reports Second Quarter 2022 Financial Results
8M ago
IART
Integra Jumps 6% On Raised 3Q Sales Outlook
Market NewsIntegra Jumps 6% On Raised 3Q Sales Outlook
2y ago
IART
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.